Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group

Article info

Clinical and epidemiological research

Extended report

Suzana Jordan Divison of Rheumatology, University Hospital Zurich, Zurich, Switzerland PubMed articles Google scholar articles
Jörg H W Distler Department of Internal Medicine, University of Erlangen-Nuremberg, Erlangen, Germany PubMed articles Google scholar articles
Britta Maurer Divison of Rheumatology, University Hospital Zurich, Zurich, Switzerland PubMed articles Google scholar articles
Dörte Huscher Charité University Hospital and German Rheumatism Research Centre, Berlin, Germany PubMed articles Google scholar articles
Jacob M van Laar Department of Rheumatology and Clinical Immunology UMC, Utrecht, The Netherlands PubMed articles Google scholar articles
Yannick Allanore Université Paris Descartes, Hôpital Cochin, Service de Rhumatologie A & INSERM U1016, Paris, France PubMed articles Google scholar articles
Oliver Distler Divison of Rheumatology, University Hospital Zurich, Zurich, Switzerland PubMed articles Google scholar articles

Correspondence to Dr Oliver Distler, Division of Rheumatology, University Hospital Zurich, Gloriastr. 25; Zurich 8091, Switzerland; Oliver.Distler{at}usz.ch

Citation

Jordan S, Distler JHW, Maurer B on behalf of the EUSTAR Rituximab study group, et al

Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group

Annals of the Rheumatic Diseases 2015;74:1188-1194.

Online issue publication

July 28, 2023

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions